MT
Therapeutic Areas
Daiichi Sankyo Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ENHERTU (fam-trastuzumab deruxtecan) | HER2+ Breast Cancer (post-neoadjuvant) | Phase 3 |
| ENHERTU | HER2+ Gynecologic Cancers | Phase 3 |
| DATROWAY (datopotamab deruxtecan) | TROP2+ Cancers | Approved |
| VANFLYTA (quizartinib) | Acute Myeloid Leukemia | Approved |
| TURALIO (pexidartinib) | Tenosynovial Giant Cell Tumor | Approved |
| INJECTAFER (ferric carboxymaltose) | Iron Deficiency | Approved |
Leadership Team at Daiichi Sankyo
KK
Ken Keller
Chairman, President & CEO of Daiichi Sankyo Inc. and Global Head of Oncology Business
KT
Ken Takeshita, MD
Global Head of Research & Development
DS
Daniel Switzer
Head of U.S. Oncology Business Division
RJ
Rich Jones
VP, Global Oncology Business Strategy & Analytics
AK
Ahmed Kotb, MD
Head of Global Oncology Medical Affairs
MG
Michael Grosso, MD, FACS
Global Head of Specialty Medicine Clinical Development
DN
Dalal Nesheiwat, PharmD
Head of R&D Operations
SM
Sandy Milligan, MD, JD
Head of Global Regulatory Affairs
MS
Michele Schmidt
Head of Asset Strategy & Project Management
DE
Dale E. Shuster, PhD
Head of Global Precision Medicine